EBEmily Burns

Emily Burns

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Emily Burns has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Acne Supplements Sold Online

    by Emily Burns, Milbrey Parke, Ariadna Perez-Sanchez, Dina Zamil, Rajani Katta

    Introduction: As no centralized database of acne supplements is available, we aimed to provide an overview of these products, with a focus on safety. Objectives: The objectives of this study were to document the number, formulation, contents, and marketing strategies utilized by acne supplements sold online. Methods: An online search was conducted between March and May 2020. Products were included in the study if they used the terms: “whitehead”, “blackhead”, or “acne”. Data were extracted from the website, box, and Supplement Facts label. Results: 49 products were identified, which contained 146 unique ingredients. These included vitamins, minerals, food extracts, botanical extracts, amino acids, animal products, and distinct microbial strains. Few (4.1%) products were tested by third parties. Conclusions: This survey of acne supplements available online raised concerns regarding lack of warning labels, teratogenicity, exceedingly large levels of vitamins and minerals, and lack of third-party testing. Given the limited regulation and oversight of dietary supplements, it is imperative that physicians educate patients on the potential risks of these products.


  • Pediatric Behҫet disease: Update in diagnosis and management

    by Emily Burns, Elizabeth Cooper, Rosemary Peterson, Lucia Z. Diaz

    Behҫet disease is a multisystem inflammatory disease and variable vessel vasculitis involving primarily the oral and genital mucosa, skin, and eyes. Diagnosis is challenging due to the lack of a specific diagnostic test and overlap with other autoinflammatory diseases. Treatment of pediatric Behҫet disease aims to reduce inflammation and prevent future flares. The goal of this review is to provide guidance on the diagnostic workup and multidisciplinary approach of pediatric Behҫet disease and review evidence-based treatment strategies for patients with refractory mucocutaneous manifestations.


  • Skin‐colored lateral forehead nodule

    by Emily Burns, Alex Chau, Carly Dunn, Denise Metry

  • Open Access

    Skin, Hair, and Nail Supplements: Marketing and Labeling Concerns

    by Ariadna C. Perez-Sanchez, Evelyne K. Tantry, Emily K. Burns, Veronica M. Perez, Sahana Prabhu, Rajani Katta

    Dietary supplements advertised to “boost collagen” or for “skin, hair, and nail” health are becoming increasingly popular, despite a lack of evidence to support their use. These products are not regulated by the United States (U.S.) Food and Drug Administration (FDA), and hence there is no centralized database listing current products. The goal of this study was to document and examine the labeling and marketing methods of these products. Supplements including the words “glow,” “beauty,” “skin,” “hair,” or “nails” on the label were included in the sample. Seven stores within a 3-mile radius were included. A total of 176 unique supplements were identified. It was found that most products lacked independent testing; many utilized outdated daily values (DVs) of nutrients. Some had confusing dosing instructions, and most products made health-related marketing claims. Dermatologists and primary care providers should be aware of the marketing claims commonly made by these products. Patients should be educated that these claims are generally not verified by independent testing agencies, the U.S. FDA, or by high-quality randomized control trials.


  • Open Access

    Risks of Skin, Hair, and Nail Supplements

    by Emily K. Burns, Ariadna Perez-Sanchez, Rajani Katta

    Citation: Burns EK, Perez-Sanchez A, Katta R. Risks of skin, hair, and nail supplements. Dermatol Pract Concept. 2020;10(4):e2020089. DOI: https://doi.org/10.5826/dpc.1004a89 Accepted: May 28, 2020; Published: October 26, 2020 Copyright: ©2020 Burns et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License BY-NC-4.0, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited. Funding: None. Competing interests: The authors have no conflicts of interest to disclose. Authorship: All authors have contributed significantly to this publication. Corresponding author: Rajani Katta, MD, 6800 West Loop South Suite 180, Bellaire, TX 77401, USA. Email: info@kattamd.com Skin, hair, and nail supplements, sometimes referred to as “beauty supplements” or “ingestible skin care”, are a large and growing industry. These products may contain vitamins and minerals, sometimes in very high doses. They may also contain herbs, hormones, microbes, or animal derivatives such as fish oils and collagen powders. Dietary supplements are regulated as foods, not drugs, by the U.S. Food and Drug Administration. Therefore, manufacturers do not need to provide any proof of safety, efficacy, or quality prior to sale. This is of serious concern, as many adverse effects due to supplement components have been reported. The potential risks cover multiple categories. These include acute toxicities such as choking, as well as chronic toxicities, such as increased risk of diabetes. Teratogenicity and interaction with drugs and laboratory testing have been documented in research studies. Other risks include potentially increased risk of cancer with long-term use, allergic reactions, and others. It is vital that physicians educate their patients on these risks. As no post-marketing surveillance programs are required for supplements, our understanding of supplement risks is incomplete. Physicians should be wary of these risks and encourage further research and regulation. Keywords : dietary supplements, toxicity, adverse effects, diet, nutrition This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


  • Necrobiosis lipoidica with rapid response to doxycycline

    by Emily Burns, Uzoamaka Ukoha, Audrey Chan

    Necrobiosis lipoidica (NL) is a rare granulomatous disease of unknown etiology. Multiple therapies may be used with varying efficacy. We report a pediatric patient with a history of type I diabetes mellitus and NL with minimal response to an ultrapotent topical steroid, topical calcineurin inhibitor, and intralesional triamcinolone, complicated by steroid atrophy, who rapidly responded after addition of doxycycline.


  • Idiopathic Facial Aseptic Granuloma in an older child: A case report in a pre‐adolescent boy

    by Emily Burns, Rosie Qin, Denise Metry

    Idiopathic facial aseptic granuloma (IFAG) is an uncommon, benign lesion that presents in the pediatric population. The diagnosis is classically associated with preschool‐aged children. Herein, we present a case of IFAG in a pre‐adolescent boy, emphasizing the importance of diagnostic consideration in older children.


  • Open Access

    Safety Concerns of Skin, Hair and Nail Supplements in Retail Stores

    by Ariadna C. Perez-Sanchez, Emily K. Burns, Veronica M. Perez, Evelyne K. Tantry, Sahana Prabhu, Rajani Katta

    Background: Dietary supplements promoted for "skin, hair, and nail" health are becoming increasingly popular, although there is a lack of regulatory oversight. As no centralized database or repository for these supplements is available, the aim of this study was to provide an overview of supplements in a sample of retail stores, with a focus on safety concerns. Methods: Dermatology supplements were defined as those that featured the words "skin", "hair", "nails", "beauty", or "glow" in the product name or tagline. Seven stores including drug, grocery, department, and cosmetics stores were surveyed within a three-mile radius. Data were extracted from the Supplement Facts label of each product. Results: A total of 176 separate supplements were identified, containing a total of 255 distinct ingredients. These included vitamins, minerals, food extracts, botanicals, animal products (collagen, fish oils), amino acids, a hormone, and distinct microbial strains. Conclusion: This survey of "dermatology" supplements available in local retailers raised several safety concerns, including potential interactions, teratogenicity risks, a lack of independent third-party testing, lack of warning labels, and nutrient "overdosing". Given limited regulation of dietary supplements, it is imperative that physicians educate patients on the potential risks. These include risks related to supplement ingredients and dosages, as well as risks related to the lack of regulatory oversight. Patients must also be educated about the multiple gaps in our knowledge of dietary supplements, especially in terms of efficacy and long-term safety.


  • Open Access

    Medicinal Nicotine Nonuse: Smokers' Rationales for Past Behavior and Intentions to Try Medicinal Nicotine in a Future Quit Attempt

    by Mph Margaret Cook-Shimanek, Msph Emily K. Burns, Arnold H. Levinson

    Nicotine replacement therapy (NRT) is a proven smoking cessation treatment. Previous research has reported low rates of NRT use among quit attempters. This study analyzed population-level nonuse rates and reasons for not using NRT. Data were from the 2008 adult Colorado Tobacco Attitudes and Behaviors Survey (TABS), a population-based, random-digit-dialed telephone survey (n = 14,156). Primary measures were past NRT nonuse and future intentions regarding NRT use among current smokers intending to quit. Multiple logistic regression was used to identify reasons for past NRT nonuse associated with intention to use NRT in the future, adjusted for factors known to influence NRT use. Nearly, 80% of 1,095 current smokers who intended to quit had never used NRT. The most common reasons for nonuse were belief that “willpower” alone is sufficient for cessation (21.5%), perceived lack of NRT effectiveness (15.6%), and cost (14.3%). Willpower was more widely reported among Hispanics than Anglos (36.9% vs. 14.7%) and nondaily versus daily smokers (30.4% vs. 12.5%). Most previous NRT nonusers reported they would use cold turkey (65.2%) in their next quit attempt; NRT was the next most common choice (15.0%). In multivariate analysis, smokers identifying cost or willpower as a reason for previous nonuse had significantly lower odds of planning to use NRT in a future quit attempt. The majority of smokers have never used NRT and do not plan to use it in the future. Cost and belief in willpower alone are significant barriers to using NRT in future smoking cessation attempt.